READY TO USE INJECTABLE PRODUCTS

Special Holiday Closure

IMPORTANT MESSAGE Dear Valued Clients, In celebration of this year’s Christmas Holiday, our company will be closed for normal business from Friday, December 24, 2021 up to Monday, January 3, 2022, inclusively. We will be open for normal business on Tuesday, January 4, 2022. Please note that the last deliveries for this year will be

Appointment Notice

Pierre Beaulieu, Vice President of Sales and Marketing, is pleased to announce the appointment of Mr. Fred Cuvelier to the position of Key Account Manager for Western Canada (British Columbia, Alberta, Saskatchewan and Manitoba), in the Sales and Marketing team. He will work under the direction of Bernard Bouchard, Director, National Sales and will officially

Our Heparin Sodium Injection has 36 month of stability

Dear Customer, Sterinova is very pleased to announce that our Ready-to-use Heparin Sodium Injection syringe 5,000 units / 0.5 mL has now a longer stability and goes from 24 months to 36 months (room temperature). We hope that this additional stability will allow you to simplify the management of this product. We would also like

HYDROmorphone Injection USP Temporary Shortage of stock

READY-TO USE SOLUTION OF HYDROMORPHONE HYDROCHLORIDE INJECTION USP, 0.4 mg / mL in 100 mL – BACKORDER NOTICE Dear Customer, Sterinova regrets to inform you of a backorder on the READY-TO USE SOLUTION OF HYDROMORPHONE HYDROCHLORIDE INJECTION USP, 0.4 mg / mL in the 100 mL format, due to an important increase in demand caused

B. Braun Melsungen AG completes acquisition of Sterinova Inc.

Saint-Hyacinthe, QC – September 29, 2021 – B. Braun Melsungen AG announces that it has acquired the minority interest of the cofounders Jean-Philippe Gentes and Bertrand Bolduc in Sterinova Inc. and now owns 100% of the company. Sterinova will continue to operate as a distinct subsidiary of B. Braun Melsungen AG. “We thank the founders